Pfizer has reached a deal worth up to $10 billion to buy weight-loss drug startup Metsera, ending a dramatic takeover battle after Ozempic maker Novo Nordisk tried to interfere in the process with a new, unsolicited offer higher than Pfizer’s previous one.
About The Author
